S&P 500   3,961.00 (+0.69%)
DOW   33,802.62 (+0.61%)
QQQ   283.30 (+0.99%)
AAPL   142.64 (+1.21%)
MSFT   246.82 (+1.00%)
META   115.55 (+1.42%)
GOOGL   93.90 (-1.10%)
AMZN   89.67 (+1.37%)
TSLA   170.97 (-1.76%)
NVDA   167.19 (+3.72%)
NIO   13.19 (+4.85%)
BABA   93.31 (+5.64%)
AMD   70.50 (+0.51%)
T   19.15 (-0.78%)
MU   55.35 (+2.84%)
CGC   3.18 (-1.85%)
F   13.16 (+0.46%)
GE   83.85 (-1.35%)
DIS   92.54 (+0.42%)
AMC   6.22 (+2.81%)
PYPL   75.27 (+1.14%)
PFE   50.82 (+1.15%)
NFLX   308.49 (+0.02%)
S&P 500   3,961.00 (+0.69%)
DOW   33,802.62 (+0.61%)
QQQ   283.30 (+0.99%)
AAPL   142.64 (+1.21%)
MSFT   246.82 (+1.00%)
META   115.55 (+1.42%)
GOOGL   93.90 (-1.10%)
AMZN   89.67 (+1.37%)
TSLA   170.97 (-1.76%)
NVDA   167.19 (+3.72%)
NIO   13.19 (+4.85%)
BABA   93.31 (+5.64%)
AMD   70.50 (+0.51%)
T   19.15 (-0.78%)
MU   55.35 (+2.84%)
CGC   3.18 (-1.85%)
F   13.16 (+0.46%)
GE   83.85 (-1.35%)
DIS   92.54 (+0.42%)
AMC   6.22 (+2.81%)
PYPL   75.27 (+1.14%)
PFE   50.82 (+1.15%)
NFLX   308.49 (+0.02%)
S&P 500   3,961.00 (+0.69%)
DOW   33,802.62 (+0.61%)
QQQ   283.30 (+0.99%)
AAPL   142.64 (+1.21%)
MSFT   246.82 (+1.00%)
META   115.55 (+1.42%)
GOOGL   93.90 (-1.10%)
AMZN   89.67 (+1.37%)
TSLA   170.97 (-1.76%)
NVDA   167.19 (+3.72%)
NIO   13.19 (+4.85%)
BABA   93.31 (+5.64%)
AMD   70.50 (+0.51%)
T   19.15 (-0.78%)
MU   55.35 (+2.84%)
CGC   3.18 (-1.85%)
F   13.16 (+0.46%)
GE   83.85 (-1.35%)
DIS   92.54 (+0.42%)
AMC   6.22 (+2.81%)
PYPL   75.27 (+1.14%)
PFE   50.82 (+1.15%)
NFLX   308.49 (+0.02%)
S&P 500   3,961.00 (+0.69%)
DOW   33,802.62 (+0.61%)
QQQ   283.30 (+0.99%)
AAPL   142.64 (+1.21%)
MSFT   246.82 (+1.00%)
META   115.55 (+1.42%)
GOOGL   93.90 (-1.10%)
AMZN   89.67 (+1.37%)
TSLA   170.97 (-1.76%)
NVDA   167.19 (+3.72%)
NIO   13.19 (+4.85%)
BABA   93.31 (+5.64%)
AMD   70.50 (+0.51%)
T   19.15 (-0.78%)
MU   55.35 (+2.84%)
CGC   3.18 (-1.85%)
F   13.16 (+0.46%)
GE   83.85 (-1.35%)
DIS   92.54 (+0.42%)
AMC   6.22 (+2.81%)
PYPL   75.27 (+1.14%)
PFE   50.82 (+1.15%)
NFLX   308.49 (+0.02%)
NASDAQ:NKTR

Nektar Therapeutics - NKTR Stock Forecast, Price & News

$2.95
+0.04 (+1.37%)
(As of 12/8/2022 11:26 AM ET)
Add
Compare
Today's Range
$2.83
$2.98
50-Day Range
$2.80
$4.28
52-Week Range
$2.73
$15.94
Volume
22,084 shs
Average Volume
2.21 million shs
Market Capitalization
$554.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.40

Nektar Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
1.92 Rating Score
Upside/​Downside
188.7% Upside
$8.40 Price Target
Short Interest
Bearish
8.93% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
0.00mentions of Nektar Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$313,411 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.14) to ($1.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

662nd out of 1,027 stocks

Pharmaceutical Preparations Industry

315th out of 503 stocks

NKTR stock logo

About Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Stock News Headlines

Nektar Therapeutics: Recovery Seems To Be A Mirage
SVB Securities Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)
Nektar's (NKTR) Q3 Earnings and Revenues Beat Estimates
Nektar Therapeutics Q3 Loss decreases, beats estimates
Nektar Therapeutics Reports Third Quarter 2022 Financial Results
PureTech Health and Nektar Therapeutics end tie-up talks
Nektar Therapeutics, PureTech End Merger Talks - Quick Facts
Nektar Therapeutics (NKTR)
Nektar Therapeutics Presents Data for...
See More Headlines
Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Company Calendar

Last Earnings
11/03/2022
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:NKTR
CUSIP
64026810
Employees
740
Year Founded
1990

Price Target and Rating

Average Stock Price Forecast
$8.40
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+184.7%
Consensus Rating
Hold
Rating Score (0-4)
1.92
Research Coverage
12 Analysts

Profitability

Net Income
$-523,840,000.00
Net Margins
-477.85%
Pretax Margin
-477.78%

Debt

Sales & Book Value

Annual Sales
$101.91 million
Book Value
$3.68 per share

Miscellaneous

Free Float
181,601,000
Market Cap
$554.45 million
Optionable
Optionable
Beta
1.00

Social Links


Key Executives

  • Mr. Howard W. RobinMr. Howard W. Robin (Age 69)
    CEO, Pres & Director
    Comp: $2.14M
  • Mr. Mark A. Wilson (Age 50)
    Chief Legal Officer & Sec.
    Comp: $798.26k
  • Dr. Jonathan Zalevsky Ph.D.Dr. Jonathan Zalevsky Ph.D. (Age 47)
    Sr. VP & Chief R&D Officer
    Comp: $1.16M
  • Mr. John P. NorthcottMr. John P. Northcott (Age 44)
    Strategic Consulting Advisor
    Comp: $1.07M
  • Ms. Jillian B. ThomsenMs. Jillian B. Thomsen (Age 56)
    Chief Financial Officer
  • Mr. Robert Bacci
    Sr. VP of HR & Facilities Operations
  • Ms. Jennifer Ruddock
    Chief Bus. Officer
  • Dr. Mary Tagliaferri L.Ac. (Age 56)
    M.D., Chief Devel. Officer
  • Dr. Brian L. Kotzin M.D. (Age 73)
    Chief Medical Officer
  • Dr. Kevin Brodbeck Ph.D.
    Sr. VP of Technical Operations













NKTR Stock - Frequently Asked Questions

Should I buy or sell Nektar Therapeutics stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 3 sell ratings, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View NKTR analyst ratings
or view top-rated stocks.

What is Nektar Therapeutics' stock price forecast for 2023?

12 Wall Street analysts have issued 1 year target prices for Nektar Therapeutics' shares. Their NKTR share price forecasts range from $3.00 to $21.00. On average, they predict the company's stock price to reach $8.40 in the next twelve months. This suggests a possible upside of 188.7% from the stock's current price.
View analysts price targets for NKTR
or view top-rated stocks among Wall Street analysts.

How have NKTR shares performed in 2022?

Nektar Therapeutics' stock was trading at $13.51 at the beginning of 2022. Since then, NKTR stock has decreased by 78.5% and is now trading at $2.91.
View the best growth stocks for 2022 here
.

When is Nektar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our NKTR earnings forecast
.

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings data on Thursday, November, 3rd. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.23. The biopharmaceutical company earned $23.63 million during the quarter, compared to analysts' expectations of $23.31 million. Nektar Therapeutics had a negative net margin of 477.85% and a negative trailing twelve-month return on equity of 81.70%.

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (18.65%), Vanguard Group Inc. (12.32%), Primecap Management Co. CA (8.74%), State Street Corp (4.18%), Bank of New York Mellon Corp (0.91%) and Dimensional Fund Advisors LP (0.67%). Insiders that own company stock include Curet Myriam, Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, R Scott Greer and Robert Chess.
View institutional ownership trends
.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $2.91.

How much money does Nektar Therapeutics make?

Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $546.93 million and generates $101.91 million in revenue each year. The biopharmaceutical company earns $-523,840,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis.

How many employees does Nektar Therapeutics have?

The company employs 740 workers across the globe.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for the company is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300.

This page (NASDAQ:NKTR) was last updated on 12/8/2022 by MarketBeat.com Staff